Acetazolamide-augmented BOLD MRI to Assess Whole-Brain Cerebrovascular Reactivity in Chronic Steno-occlusive Disease Using Principal Component Analysis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 36916889.
- Also identified by DOI 10.1148/radiol.221473 and PMC identifier 10140639.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Background Exhaustion of cerebrovascular reactivity (CVR) portends increased stroke risk. Acetazolamide-augmented blood oxygenation level-dependent (BOLD) MRI has been used to estimate CVR, but low signal-to-noise conditions relegate its use to terminal CVR (CVR<sub>end</sub>) measurements that neglect dynamic features of CVR. Purpose To demonstrate comprehensive characterization of acetazolamide-augmented BOLD MRI response in chronic steno-occlusive disease using a computational framework to precondition signal time courses for dynamic whole-brain CVR analysis. Materials and Methods This study focused on retrospective analysis of consecutive patients with unilateral chronic steno-occlusive disease who underwent acetazolamide-augmented BOLD imaging for recurrent minor stroke or transient ischemic attack at an academic medical center between May 2017 and October 2020. A custom principal component analysis-based denoising pipeline was used to correct spatially varying non-signal-bearing contributions obtained by a local principal component analysis of the MRI time series. Standard voxelwise CVR<sub>end</sub> maps representing terminal responses were produced and compared with maximal CVR (CVR<sub>max</sub>) as isolated from binned (per-repetition time) denoised BOLD time course. A linear mixed-effects model was used to compare CVR<sub>max</sub> and CVR<sub>end</sub> in healthy and diseased hemispheres. Results A total of 23 patients (median age, 51 years; IQR, 42-61, 13 men) who underwent 32 BOLD examinations were included. Processed MRI data showed twofold improvement in signal-to-noise ratio, allowing improved isolation of dynamic characteristics in signal time course for sliding window CVR<sub>max</sub> analysis to the level of each BOLD repetition time (approximately 2 seconds). Mean CVR<sub>max</sub> was significantly higher than mean CVR<sub>end</sub> in diseased (5.2% vs 3.8%, <i>P</i> < .01) and healthy (5.5% vs 4.0%, <i>P</i> < .01) hemispheres. Several distinct time-signal signatures were observed, including nonresponsive; delayed/blunted; brisk; and occasionally nonmonotonic time courses with paradoxical features in normal and abnormal tissues (ie, steal and reverse-steal patterns). Conclusion A principal component analysis-based computational framework for analysis of acetazolamide-augmented BOLD imaging can be used to measure unsustained CVR<sub>max</sub> through twofold improvements in signal-to-noise ratio. © RSNA, 2023 <i>Supplemental material is available for this article.</i>
Medical subject headings
- Acetazolamide
- Cerebrovascular Disorders